JP2010511626A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511626A5
JP2010511626A5 JP2009539490A JP2009539490A JP2010511626A5 JP 2010511626 A5 JP2010511626 A5 JP 2010511626A5 JP 2009539490 A JP2009539490 A JP 2009539490A JP 2009539490 A JP2009539490 A JP 2009539490A JP 2010511626 A5 JP2010511626 A5 JP 2010511626A5
Authority
JP
Japan
Prior art keywords
alkyl
nhc
compound
independently
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009539490A
Other languages
English (en)
Japanese (ja)
Other versions
JP5211063B2 (ja
JP2010511626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/085962 external-priority patent/WO2008067481A1/en
Publication of JP2010511626A publication Critical patent/JP2010511626A/ja
Publication of JP2010511626A5 publication Critical patent/JP2010511626A5/ja
Application granted granted Critical
Publication of JP5211063B2 publication Critical patent/JP5211063B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009539490A 2006-11-30 2007-11-29 アザ−インドリル化合物及び使用方法 Expired - Fee Related JP5211063B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US60/868,055 2006-11-30
US91762007P 2007-05-11 2007-05-11
US60/917,620 2007-05-11
US94474307P 2007-06-18 2007-06-18
US60/944,743 2007-06-18
PCT/US2007/085962 WO2008067481A1 (en) 2006-11-30 2007-11-29 Aza-indolyl compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2010511626A JP2010511626A (ja) 2010-04-15
JP2010511626A5 true JP2010511626A5 (cg-RX-API-DMAC7.html) 2010-12-24
JP5211063B2 JP5211063B2 (ja) 2013-06-12

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539490A Expired - Fee Related JP5211063B2 (ja) 2006-11-30 2007-11-29 アザ−インドリル化合物及び使用方法

Country Status (14)

Country Link
US (1) US7855216B2 (cg-RX-API-DMAC7.html)
EP (1) EP2099796B1 (cg-RX-API-DMAC7.html)
JP (1) JP5211063B2 (cg-RX-API-DMAC7.html)
AR (1) AR064031A1 (cg-RX-API-DMAC7.html)
AT (1) ATE511509T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007325123B2 (cg-RX-API-DMAC7.html)
CA (1) CA2672327A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007003444A1 (cg-RX-API-DMAC7.html)
DK (1) DK2099796T3 (cg-RX-API-DMAC7.html)
PE (1) PE20081354A1 (cg-RX-API-DMAC7.html)
PL (1) PL2099796T3 (cg-RX-API-DMAC7.html)
PT (1) PT2099796E (cg-RX-API-DMAC7.html)
TW (1) TW200829586A (cg-RX-API-DMAC7.html)
WO (1) WO2008067481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297070A2 (en) * 2008-07-03 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Compounds and processes for production of radiopharmaceuticals
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
MX340392B (es) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
JP5985401B2 (ja) 2010-03-09 2016-09-06 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法
CN103153063B (zh) 2010-07-30 2016-02-17 肿瘤疗法科学股份有限公司 喹啉衍生物及含有其的melk抑制剂
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
EP2916859B1 (en) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
PL3624796T3 (pl) 2017-05-19 2025-06-30 Nflection Therapeutics, Inc. Związki pirolopirydyno-anilinowe do leczenia zaburzeń skórnych
DK3624795T3 (da) 2017-05-19 2022-05-23 Nflection Therapeutics Inc Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser
US11859252B2 (en) 2017-09-08 2024-01-02 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US11572344B2 (en) 2018-11-20 2023-02-07 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CA3120352A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
US12310950B2 (en) 2021-11-23 2025-05-27 Nflection Therapeutics, Inc. Formulations of pyrrolopyridine-aniline compounds
CA3247162A1 (en) * 2022-01-28 2023-08-03 Insilico Medicine Ip Limited Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses
WO2023166450A1 (ko) * 2022-03-04 2023-09-07 삼진제약주식회사 신규한 헤테로 고리 화합물 및 이를 포함하는 약학적 조성물
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
KR20250067072A (ko) * 2023-11-07 2025-05-14 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ES2330628T3 (es) * 2002-04-23 2009-12-14 Aventis Pharmaceuticals Inc. Ester del acido 3-(amino sustituido)-1h-indol-2-carboxilico y derivados del ester del acido 3-(amino sustituido)-benzo(b)tiofeno-2-carboxilico como imhibidores de expresion del gen de interleucina-4.
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
DE102005013621A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Similar Documents

Publication Publication Date Title
JP2010511626A5 (cg-RX-API-DMAC7.html)
JP2010501584A5 (cg-RX-API-DMAC7.html)
JP2013503846A5 (cg-RX-API-DMAC7.html)
JP2009504763A5 (cg-RX-API-DMAC7.html)
JP2016518434A5 (cg-RX-API-DMAC7.html)
JP2008525416A5 (cg-RX-API-DMAC7.html)
JP2011527334A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2012505871A5 (cg-RX-API-DMAC7.html)
JP2012530713A5 (cg-RX-API-DMAC7.html)
JP2010527913A5 (cg-RX-API-DMAC7.html)
JP2009539828A5 (cg-RX-API-DMAC7.html)
JP2006151984A5 (cg-RX-API-DMAC7.html)
JP2011521938A5 (cg-RX-API-DMAC7.html)
JP2010540525A5 (cg-RX-API-DMAC7.html)
JP2010509366A5 (cg-RX-API-DMAC7.html)
JP2010501478A5 (cg-RX-API-DMAC7.html)
JP2016506387A5 (cg-RX-API-DMAC7.html)
JP2011527335A5 (cg-RX-API-DMAC7.html)
JP2019500387A5 (cg-RX-API-DMAC7.html)
JP2011520815A5 (cg-RX-API-DMAC7.html)
JP2011527332A5 (cg-RX-API-DMAC7.html)
JP2012525393A5 (cg-RX-API-DMAC7.html)
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2017523169A5 (cg-RX-API-DMAC7.html)